mTOR signaling in osteosarcoma: Oncogenesis and therapeutic aspects (Review)

  • Authors:
    • Kai Hu
    • Hai-Bo Dai
    • Zhi-Long Qiu
  • View Affiliations

  • Published online on: July 8, 2016     https://doi.org/10.3892/or.2016.4922
  • Pages: 1219-1225
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that belongs to the phosphoinositide-3-kinase (PI3K)-related kinase family. Oncogenic activation of mTOR signaling significantly contributes to the progression of different types of cancers including osteosarcoma (OS; the most common primary malignant tumor of bone). In the present study, we review the association of the mTOR signaling pathway with OS, and the possible effective treatment strategies by targeting this pathway. In the metastatic behavior of OS, one of the most common actionable aberrations was found in the PI3K/Akt/mTOR pathway. Upon phosphorylation, activated mTOR contributes to OS cellular transformation and poor cancer prognosis via downstream effectors such as S6K1, 4EBP1 and eIF4E, which are overexpressed in OS. Targeting the mTOR complex is a significant approach in cancer therapeutic research, and of course, rapamycin is the primary inhibitor of mTOR. Various other chemotherapeutic molecules have also shown potential activity against mTOR. As mTOR is a new promising oncological target and blockade of the mTOR pathway with selective inhibitors has significant potential in OS therapeutic research, the development of the optimal dose, regimen and a rationale for the use of mTOR inhibitors in combination with other anticancer agents may provide a successful treatment strategy for OS.
View Figures
View References

Related Articles

Journal Cover

September-2016
Volume 36 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hu K, Dai H and Qiu Z: mTOR signaling in osteosarcoma: Oncogenesis and therapeutic aspects (Review). Oncol Rep 36: 1219-1225, 2016.
APA
Hu, K., Dai, H., & Qiu, Z. (2016). mTOR signaling in osteosarcoma: Oncogenesis and therapeutic aspects (Review). Oncology Reports, 36, 1219-1225. https://doi.org/10.3892/or.2016.4922
MLA
Hu, K., Dai, H., Qiu, Z."mTOR signaling in osteosarcoma: Oncogenesis and therapeutic aspects (Review)". Oncology Reports 36.3 (2016): 1219-1225.
Chicago
Hu, K., Dai, H., Qiu, Z."mTOR signaling in osteosarcoma: Oncogenesis and therapeutic aspects (Review)". Oncology Reports 36, no. 3 (2016): 1219-1225. https://doi.org/10.3892/or.2016.4922